ストックスクリーナーアプリを入手
990.33
0.72%
7.07
アフターアワーズ：
985.00
-5.33
-0.54%
前日終値:
$983.26
開ける：
$975
24時間の取引高:
2.62M
Relative Volume:
0.82
時価総額：
$884.36B
収益：
$65.18B
当期純損益:
$20.64B
株価収益率:
43.84
EPS:
22.5894
ネットキャッシュフロー:
$5.96B
1週間 パフォーマンス:
-5.86%
1か月 パフォーマンス:
-6.41%
6か月 パフォーマンス:
+36.18%
1年 パフォーマンス:
+8.50%
1日の値動き範囲:
$966.09
$991.22
1週間の範囲:
$965.60
$1,056.20
52週間の値動き範囲:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Compare LLY vs JNJ, ABBV, NVS, AZN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
990.33 | 878.04B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
240.40 | 577.48B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
230.11 | 410.83B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
160.12 | 307.23B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
194.22 | 306.31B | 58.80B | 10.24B | 8.98B | 3.2788 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-12-16 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | 繰り返されました | BofA Securities | Buy |
| 2025-12-15 | 繰り返されました | Goldman | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-11-10 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 繰り返されました | BMO Capital Markets | Outperform |
| 2025-10-14 | アップグレード | Erste Group | Hold → Buy |
| 2025-09-17 | ダウングレード | Berenberg | Buy → Hold |
| 2025-08-27 | アップグレード | HSBC Securities | Reduce → Hold |
| 2025-08-18 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | ダウングレード | Erste Group | Buy → Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-09-13 | 再開されました | Citigroup | Buy |
| 2024-08-12 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-02-21 | ダウングレード | DZ Bank | Buy → Hold |
| 2024-02-16 | 繰り返されました | Morgan Stanley | Overweight |
| 2023-12-21 | ダウングレード | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-20 | 再開されました | UBS | Buy |
| 2023-08-09 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-26 | 繰り返されました | Citigroup | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-24 | 繰り返されました | BofA Securities | Buy |
| 2023-05-24 | 繰り返されました | UBS | Buy |
| 2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-15 | ダウングレード | Societe Generale | Hold → Sell |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-09-22 | アップグレード | UBS | Neutral → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-03-10 | 開始されました | Daiwa Securities | Outperform |
| 2022-01-21 | アップグレード | DZ Bank | Hold → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-16 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-16 | 繰り返されました | BofA Securities | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-10-11 | アップグレード | Berenberg | Hold → Buy |
| 2021-09-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-05 | アップグレード | DZ Bank | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-06-24 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2021-01-19 | アップグレード | Mizuho | Neutral → Buy |
| 2020-12-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-09-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-04-21 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2019-12-18 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-04-24 | アップグレード | Edward Jones | Hold → Buy |
| 2019-04-11 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-03-12 | 開始されました | JP Morgan | Overweight |
| 2019-01-23 | 開始されました | UBS | Buy |
| 2018-11-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-10-31 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-10-01 | 繰り返されました | SunTrust | Buy |
| 2018-09-26 | 再開されました | JP Morgan | Overweight |
すべてを表示
Lilly Eli Co (LLY) 最新ニュース
Upper Macungie approves tax breaks for Eli Lilly’s proposed manufacturing campus - WFMZ.com
Eli Lilly and Company (NYSE:LLY) Trading Down 2.1%Here's Why - MarketBeat
Novo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investors - The Motley Fool
Eli Lilly Just Launched a New Program to Make GLP‑1 Weight‑Loss Drugs Cheaper for Millions of Workers - inc.com
Teladoc Health joins Eli Lilly Employer Connect platform to expand workplace health options - Traders Union
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? - AOL.com
Morgan Stanley reiterates Eli Lilly stock rating on new obesity platform - Investing.com
Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear? - Yahoo Finance UK
Eli Lilly (LLY) Launches Employer Connect for Obesity Drug Acces - GuruFocus
Eli Lilly and Company $LLY Shares Sold by Orion Porfolio Solutions LLC - MarketBeat
Eli Lilly Targets Employer Coverage Gap With New Obesity Drug Access Platform - Benzinga
This Under-the-Radar Stock Could Be the Next Big SplitAnd Early Investors Could Win Big - AOL.com
Lilly launches employer platform for obesity drug access - Investing.com
Eli Lilly and Co's first large-scale AI factory worldwide has been put into operation, equipped with over 1,000 GPUs. - 富途牛牛
Lilly launches employer-connect platform to broaden weight-loss drug access - Reuters
Eli Lilly launches program for employers to subsidize cost of obesity drug outside insurance - statnews.com
Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S. - CNBC
Quantbot Technologies LP Cuts Stake in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Acquired by Davidson Capital Management Inc. - MarketBeat
Crossmark Global Holdings Inc. Sells 1,008 Shares of Eli Lilly and Company $LLY - MarketBeat
Corient IA LLC Acquires 1,000 Shares of Eli Lilly and Company $LLY - MarketBeat
Cambria Investment Management L.P. Purchases 1,026 Shares of Eli Lilly and Company $LLY - MarketBeat
Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients | Eli Lilly and Company - Eli Lilly
Eli Lilly confirms oral GLP-1 weight-loss drug being evaluated by TGA - AFR
Eli Lilly’s Nvidia AI Deal And Pipeline Progress Versus Rich Valuation - simplywall.st
Eli Lilly and Company completed the acquisition of Ventyx Biosciences, Inc. from New Science Ventures, LLC, Affinity Asset Advisors, LLC, The Vanguard Group, Inc., and others. - marketscreener.com
Eli Lilly and booming weight-loss pharma industry now 20% of Irish goods exports - Irish Examiner
Ventyx Biosciences completes $1.2 billion acquisition by Eli Lilly, delists from Nasdaq - Investing.com India
Eli Lilly Unusual Options Activity For March 04 - Benzinga
Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval - Reuters
Eli Lilly & Co (NYSE:LLY): A High-Growth Dividend Stock for Discerning Investors - ChartMill
Richard C. Young & CO. LTD. Makes New $13.88 Million Investment in Eli Lilly and Company $LLY - MarketBeat
Picton Mahoney Asset Management Lowers Holdings in Eli Lilly and Company $LLY - MarketBeat
GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - GlobeNewswire Inc.
2 Top Growth Stocks to Buy in the First Half of 2026 - AOL.com
Does Lilly’s Broad Pipeline Wins in Obesity and Immunology Reshape the Bull Case for LLY? - simplywall.st
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,300 - 富途牛牛
Eli Lilly and Company (NYSE:LLY) Shares Down 1%Should You Sell? - MarketBeat
Eli Lilly (LLY) Monitored as FDA Targets Telehealth Firms for Mi - GuruFocus
Eli Lilly & Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Eli Lilly and Company $LLY Shares Bought by Victory Capital Management Inc. - MarketBeat
Lilly in the Valley: An Inside Look at Eli Lilly’s Lehigh Valley Investment - Fairfield Sun Times
Eli Lilly and Company $LLY Stock Position Lowered by State Farm Mutual Automobile Insurance Co. - MarketBeat
William Blair Investment Management LLC Lowers Holdings in Eli Lilly and Company $LLY - MarketBeat
South Dakota Investment Council Has $43.08 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
CI Investments Inc. Has $256.59 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen - Eli Lilly and Company
Eli Lilly and Company (NYSE:LLY) Trading Down 3.2%Time to Sell? - MarketBeat
Fisher Asset Management Boosts Eli Lilly Stake - National Today
First Long Island Investors Boosts Eli Lilly Stake - National Today
Longview Advantage ETF Trims Stake in Eli Lilly and Co - National Today
Lilly Eli Co (LLY) 財務データ
収益
当期純利益
現金流量
EPS
0.32%
0.96%
大文字化:
|
ボリューム (24 時間):